GABAA Receptor Modulator for Neuropathic Pain
Solution Overview
Problem
Current therapies for neuropathic pain, such as trigeminal neuralgia and postoperative pain, are often ineffective and associated with undesirable side effects, and there is a need for treatments that can modify the disease rather than just provide symptomatic relief, particularly those that do not involve addictive substances like opioids.
Innovation Solution
The use of 2-(3-(3-(2,4-dimethoxypyrimidin-5-yl)phenyl)-3H-imidazo[4,5-b]pyridin-6-yl)propan-2-ol, a GABAA receptor modulator, which selectively targets α2 and α3 subunits to provide analgesia without the adverse effects of traditional anticonvulsants like carbamazepine, and can be administered acutely or prophylactically to build nociceptive tolerance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies for neuropathic pain (such as opioids and traditional anticonvulsants) are used, then pain relief is achieved, but addictive side effects and dose-limiting toxicities occur
Solution Approach 1:
The patent applies local quality by designing a GABAA receptor modulator with selective affinity for specific subunit compositions (particularly α2/α3-containing receptors) rather than non-selective action. This subtype selectivity localizes the pharmacological effect to specific receptor populations in pain pathways, achieving analgesia while avoiding side effects associated with non-selective GABAA modulation (such as sedation and dependency linked to α1/α5 subunits).
Solution Approach 2:
The invention changes the pharmacological parameter of receptor selectivity by developing a compound with optimized binding characteristics for specific GABAA receptor subtypes. This parameter change from non-selective to selective modulation transforms the therapeutic profile, maintaining pain relief efficacy while eliminating addictive properties associated with traditional opioids and anticonvulsants.
2Reliability
If current therapies provide symptomatic relief, then pain management is achieved, but disease modification capacity is lost
Solution Approach 1:
The patent applies preliminary action by using GABAA receptor modulation to prevent central sensitization and neuroplastic changes that underlie neuropathic pain development. By enhancing inhibitory tone early in the pain pathway (at the level of spinal cord dorsal horn lamina II), the compound prevents the establishment of maladaptive neural circuits, thereby modifying the disease process before chronic pain becomes entrenched.
3Reliability
If selective GABAA receptor modulators targeting α2/α3 subunits are used, then analgesic effects are improved, but side effect profile may worsen
Solution Approach 1:
The patent refines local quality by achieving even greater subtype selectivity within the GABAA receptor family. The compound demonstrates preferential binding to receptors containing specific subunit combinations (α2/α3) while minimizing interaction with other subtypes, thereby concentrating therapeutic effects in pain-related neural circuits while sparing brain regions responsible for sedation and cognitive functions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This compound achieves significant analgesic effects comparable to carbamazepine without its side effects, offering a more effective and safer treatment option for neuropathic pain, including trigeminal neuralgia and postoperative pain, by modulating the GABAA receptor complex and reducing hyperalgesia and allodynia, and can be used prophylactically to build nociceptive tolerance, reducing the need for opioids.
Implementation Method 1
The GABAA receptors are ligand gated channels which exists in multiple isoforms. Each receptor is a pentameric complex comprising subunits drawn from α1-6, β1-3, γ1-3, δ, ε and θ subunit isoforms.
Data Source
AI summary
The present invention relates to the use of 2-(3-(3-(2,4-dimethoxypyrimidin-5-yl)phenyl)-3H-imidazo[4,5-b]pyridin-6-yl)propan-2-ol or a pharmaceutically acceptable salt thereof, which is a known GABA receptor modulator, for the treatment of disorders characterized by severe pain, such as trigeminal neuralgia and postoperative pain.